<DOC>
	<DOCNO>NCT02322281</DOCNO>
	<brief_summary>The purpose study compare anti-tumor efficacy oral single-agent rociletinib , measure investigator assessment PFS , single-agent cytotoxic chemotherapy patient EGFR-mutated , advanced/metastatic NSCLC failure least 1 previous EGFR-directed TKI least 1 line platinum-containing doublet chemotherapy .</brief_summary>
	<brief_title>TIGER-3 : Open Label , Multicenter Study Rociletinib ( CO-1686 ) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy Patients With Mutant EGFR NSCLC Who Have Failed Least One Previous EGFR-Directed TKI Platinum-doublet Chemotherapy</brief_title>
	<detailed_description>This Phase 3 , randomize , open-label , multicenter study evaluate safety efficacy oral rociletinib 500 mg BID 625 mg BID compare single-agent cytotoxic chemotherapy , patient previously treat mutant EGFR NSCLC . Eligible patient mutant EGFR NSCLC previously treat least 1 EGFR inhibitor least 1 line platinum-containing chemotherapy doublet advanced/metastatic NSCLC . After provide informed consent participate screen confirm eligibility , patient randomize 1:1:1 receive either oral rociletinib 500 mg BID , oral rociletinib 625 mg BID , single-agent cytotoxic chemotherapy ( investigator choice pemetrexed , gemcitabine , docetaxel , paclitaxel ; choice chemotherapy agent must specify randomization ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>All patient must meet follow inclusion criterion : 1 . Histologically cytologically confirm metastatic unresectable locally advanced NSCLC radiological progression recent therapy receive 2 . Documented evidence tumor 1 EGFR activate mutation exclude exon 20 insertion 3 . Disease progression confirm radiological assessment receive treatment single agent EGFRTKI ( e.g. , erlotinib , gefitinib , afatinib , dacomitinib ) EGFRTKI combination target therapy ( e.g . bevacizumab , immunotherapy ) 4 . Multiple line prior treatment permit specified order treatment , course treatment history , patient must receive radiologically documented disease progression follow : At least 1 line prior treatment singleagent EGFRTKI ( e.g. , erlotinib , gefitinib , afatinib , dacomitinib ) If EGFRTKI component recent treatment line , washout period EGFRTKI minimum 3 day start study drug treatment AND A platinumcontaining doublet chemotherapy ( either progress therapy complete least 4 cycle without progression subsequent progression treatmentfree interval maintenance treatment ) . If cytotoxic chemotherapy component recent treatment line , treatment chemotherapy complete least 14 day prior start study treatment . When EGFRTKI give combination platinumcontaining doublet chemotherapy , treatment EGFRTKI may continue least 3 day start treatment . 5 . Have undergone biopsy either primary metastatic tumor tissue within 60 day prior start treatment tissue send central laboratory prior randomization 6 . Measureable disease accord RECIST Version 1.1 7 . Life expectancy least 3 month 8 . ECOG performance status 0 1 9 . Age ≥ 18 year ( certain territory , minimum age requirement may higher e.g. , age ≥ 20 year Japan Taiwan , age ≥ 21 year Singapore ) 10 . Patients recover National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Grade ≤ 1 significant chemotherapyrelated toxicity 11 . Adequate hematological biological function 12 . Written consent Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve ICF study specific evaluation Any follow criterion exclude patient study participation : 1 . Any malignancy associate high mortality risk within next 5 year patient may ( necessarily ) currently receive treatment Patients history malignancy completely treat , evidence cancer currently , permit enroll trial provide chemotherapy complete &gt; 6 month prior and/or bone marrow transplant &gt; 2 year prior 2 . Known preexist interstitial lung disease 3 . Tumor small cell transformation local assessment , irrespective presence T790M+ component 4 . Patients leptomeningeal carcinomatosis exclude . Other central nervous system ( CNS ) metastases permit treated , asymptomatic , stable ( require steroid least 2 week prior randomization patient neurologically stable i.e . free new symptom brain metastasis ) 5 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication ( know effect QT ) start protocolspecified treatment ( see http : //crediblemeds.org/ list QTprolonging medication ) 6 . Prior treatment rociletinib , drug target T790M+ mutant EGFR spar WTEGFR include limited osimertinib , HM61713 , TAS121 7 . Any contraindication therapy pemetrexed , paclitaxel , gemcitabine docetaxel unless contraindication respect one drug affect use others comparator rociletinib 8 . Any following cardiac abnormality history : 1 . Clinically significant abnormal 12lead ECG , QT interval correct use Fridericia 's method ( QTCF ) &gt; 450 msec 2 . Inability measure QT interval ECG 3 . Personal family history long QT syndrome 4 . Implantable pacemaker implantable cardioverter defibrillator 5 . Resting bradycardia &lt; 55 beats/min 9 . Nonstudy related surgical procedure ≤ 7 day prior randomization . In case , patient must sufficiently recover stable treatment administration 10 . Females pregnant breastfeed 11 . Refusal use adequate contraception fertile patient ( female male ) treatment 6 month last dose study treatment ( rociletinib chemotherapy irrespective single cytotoxic agent use ) 12 . Presence serious unstable concomitant systemic disorder incompatible clinical study ( e.g. , substance abuse , uncontrolled intercurrent illness include uncontrolled diabetes , active infection , arterial thrombosis , symptomatic pulmonary embolism ) 13 . Any reason investigator considers patient participate study 14 . Treatment live vaccine initiate less 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>locally advanced</keyword>
	<keyword>lung</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>T790M</keyword>
	<keyword>CO-1686</keyword>
	<keyword>unresectable</keyword>
	<keyword>recurrent</keyword>
	<keyword>EGFR-directed therapy</keyword>
	<keyword>irreversible EGFR inhibitor</keyword>
	<keyword>TIGER</keyword>
	<keyword>Rociletinib</keyword>
</DOC>